Preparation method and application of 8-(diphenylphosphine)quinoline iron complex catalyst

By using the 8-(diphenylphosphine)quinoline iron complex catalyst, the problems of long reaction time, harsh conditions and poor selectivity in reducing cyclic lactam are solved, and hydrogenation with high selectivity and high yields are achieved Response, has good application value.

CN115583979BActive Publication Date: 2024-11-01ZHEJIANG CHANGHAI PHARM CO LTD +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202211260284.9
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2022-10-14
Publication Date
2024-11-01
Estimated Expiration
2042-10-14

AI Technical Summary

Technical Problem

The existing catalysts in reducing dimethylaminomethylene as methyl in cyclic lactam have problems such as excessive reaction time, harsh conditions and difficult to regulate stereoselectivity, and poor selectivity and low overall yield.

Method used

Using the 8-(diphenylphosphine)quinoline iron complex as a catalyst, the 8-(diphenylphosphine)quinoline iron complex is formed by constant temperature reaction with ferrous chloride in aprotic polar solvent, for use in Catalyzed the selective hydrogenation of (2S,4S)-N-Boc-4-methylpyroglutamate.

Benefits of technology

It has achieved high selectivity and good hydrogenation properties of the catalyst, mild reaction conditions and high reaction yield, and has good promotion and application value.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN115583979B_ABST
    Figure CN115583979B_ABST
Patent Text Reader

Abstract

The invention belongs to the field of organic synthesis, specifically to the field of drug synthesis technology, and relates to a preparation method and application of a 8-(diphenylphosphine) quinoline iron complex catalyst. Its preparation method is: in a non-protonic polar solvent system, 8-(diphenylphosphine) quinoline is used as a skeleton, and reacts with a metal ligand ferrous chloride to obtain an 8-(diphenylphosphine) quinoline iron complex catalyst. In the present invention, the catalyst has good stability, efficient catalytic activity and excellent catalytic hydrogenation selectivity, and shows good catalytic performance in the preparation of drugs and intermediates such as (2S, 4S)-N-Boc-4-methylpyroglutamate methyl ester and minocycline, and the characteristics of mild reaction conditions and high reaction yield.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of organic synthesis, specifically to the technical field of drug synthesis, and relates to a preparation method of an 8-(diphenylphosphine)quinoline iron complex catalyst and application thereof. Background Art

[0002] (2S,4S)-N-Boc-4-methylpyroglutamate methyl ester is an important organic synthesis intermediate, widely used in chemical pharmaceutical, feed and fine chemical industries. In the field of chemical pharmaceutical, (2S,4S)-N-Boc-4-methylpyroglutamate methyl ester is used to synthesize AMPA-type glutamate antagonists, synthesize Rho-kinase inhibitors, synthesize hepatitis C virus inhibitor biphenylimidazole, and prepare dipeptidyl peptidase IV (DPP-4) inhibitors. In the field of fine chemicals, (2S,4S)-N-Boc-4-methylpyroglutamate methyl ester can be directly reduced by sodium borohydride to form [(2S,4R)-2-N-BOC-amino-4-methyl] pentanediol, or reduced by BH3·Me2S reagent to (2R,4S)-4-methyl-N-Boc-4-methyl-2-pyrrolidinecarboxylic acid ethyl ester.

[0003] At present, the literature reports the following methods for reducing the dimethylaminomethylene group of the ortho position of cyclic lactam to methyl group:

[0004] (1) Lin Xianfeng et al. used tert-butoxybis(dimethylamino)methane as a methylating agent to prepare 5-fluoro-3-methylindolin-2-one. The system used methanol as a solvent and used cheap sodium borohydride to reduce the dimethylaminomethylene group to a methyl group. The reaction route is as follows:

[0005]

[0006] (2) Douglas W. Young et al. used Boc-L-pyroglutamic acid ethyl ester as the starting material, first used tert-butoxybis(dimethylamino)methane for enamination to generate (2S)-N-Boc-4-dimethylaminomethylene pyroglutamic acid ethyl ester, and then used H2 / 10% Pd-C as a reducing agent and stirred the reaction at room temperature for 115 hours to prepare (2S,4S)-N-Boc-4-methylpyroglutamic acid ethyl ester. The reaction has certain disadvantages, such as long reaction time, harsh reduction conditions, and difficulty in controlling stereoselectivity. The reaction route is as follows:

[0007]

[0008] When diisobutylaluminum hydride is used as a reducing agent, the reaction generates 64% of N-Boc-4-methylenepyroglutamate methyl ester and 19% of N-Boc-4-dimethylaminomethylenepyroglutamate methyl ester. The reaction route is as follows:

[0009]

[0010] (3) Sergey V. Ryabukhin et al. applied this method to the study of carbonyl-α-methylation reaction. The study showed that the reaction using H2 / Pd-C to reduce carbonyl-α-dimethylaminomethylene has a wide range of substrate applicability, but dimethylaminomethylene is not easy to be completely reduced to methyl, the reduction reaction selectivity is poor, and the overall yield is not high. The reaction route is as follows:

[0011]

[0012] In order to overcome the shortcomings of the above technologies, the market urgently needs a catalyst that is both active and selective. Summary of the invention

[0013] In view of the problems in the prior art, the present invention provides a method for preparing an 8-(diphenylphosphine)quinoline iron complex catalyst, wherein 8-(diphenylphosphine)quinoline is used as a framework to coordinate iron ions to form the 8-(diphenylphosphine)quinoline iron complex catalyst, and the catalyst has good selective catalytic hydrogenation performance and good promotion and application value.

[0014] In order to achieve the above technical objectives, the technical solution of the present invention is:

[0015] A method for preparing an 8-(diphenylphosphine)quinoline iron complex catalyst, wherein the 8-(diphenylphosphine)quinoline iron complex catalyst has a structure of the following formula I:

[0016]

[0017] The preparation method of the 8-(diphenylphosphine)quinoline iron complex catalyst comprises the following steps: in a glove box, in the presence of a non-protonic polar solvent, using 8-(diphenylphosphine)quinoline as a skeleton, and reacting with a metal ligand ferrous chloride at a constant temperature for 12 hours to obtain the 8-(diphenylphosphine)quinoline iron complex catalyst, and the reaction equation is as follows:

[0018]

[0019] The aprotic polar solvent is one of tetrahydrofuran, dimethyl sulfoxide, N,N-dimethylformamide, 1,3-dimethyl-2-imidazolidinone and hexamethylphosphoric triamide.

[0020] The temperature of the isothermal reaction is 40-80°C, preferably 60°C.

[0021] The 8-(diphenylphosphine)quinoline iron complex catalyst is used for the preparation of (2S, 4S)-N-Boc-4-methylpyroglutamate methyl ester and minocycline hydrochloride crude product.

[0022] The reaction formula for preparing (2S,4S)-N-Boc-4-methylpyroglutamate methyl ester by selective hydrogenation of (2S)-N-Boc-4-dimethylaminomethylenepyroglutamate methyl ester is as follows:

[0023]

[0024] The reaction formula for preparing crude minocycline hydrochloride by selective hydrogenation of a minocycline intermediate hydroazo is as follows:

[0025]

[0026] It can be seen from the above description that the present invention has the following advantages:

[0027] 1. The present invention solves the technical defects of existing catalysts, and uses 8-(diphenylphosphine)quinoline as a framework to coordinate iron ions to form an 8-(diphenylphosphine)quinoline iron complex catalyst. The complex catalyst is a multidentate ligand that can provide two different electron-donating groups, nitrogen and phosphine, as soft and hard electron donors, respectively, to form a stable or semi-stable metal complex with a transition metal, so that it exhibits higher reduction activity and stereoselectivity in catalytic hydrogenation reactions.

[0028] 2. The 8-(diphenylphosphine)quinoline iron complex catalyst prepared by the present invention has good selective catalytic hydrogenation performance and has good promotion and application value. BRIEF DESCRIPTION OF THE DRAWINGS

[0029] Figure 1 X-ray single crystal image of 8-(diphenylphosphine)quinoline iron complex

[0030] Figure 2 This is the NMR phosphorus spectrum of 8-(diphenylphosphine)quinoline iron complex;

[0031] Figure 3 This is the H NMR spectrum of 8-(diphenylphosphine)quinoline iron complex;

[0032] Figure 4 This is the C NMR spectrum of 8-(diphenylphosphine)quinoline iron complex;

[0033] Figure 5 is the H NMR spectrum of (2S,4S)-N-Boc-4-methylpyroglutamate;

[0034] Figure 6 is the NMR carbon spectrum of (2S,4S)-N-Boc-4-methylpyroglutamate;

[0035] Figure 7is the NMR DEPT spectrum of (2S,4S)-N-Boc-4-methylpyroglutamate;

[0036] Figure 8 This is the H NMR spectrum of minocycline hydrochloride. DETAILED DESCRIPTION

[0037] Combination Figures 1 to 8 , describes in detail a specific embodiment of the present invention, but does not limit the claims of the present invention.

[0038] Example 1

[0039] Preparation of 8-(diphenylphosphine)quinoline iron complex catalyst:

[0040] In a glove box, FeCl2·4H2O (1.0 g, 0.5 mmol), tetrahydrofuran (15 mL) and 8-(diphenylphosphino)quinoline (0.33 g, 1.05 mmol) were added to a pressure test tube in sequence, and the mixture was kept warm at 60°C for 12 h. After the reaction, part of the solvent was removed under vacuum until about 5 mL remained, 25 mL of anhydrous ether was added, and a large amount of light green solid precipitated. The solid was filtered through a sand core under N2 atmosphere, and the solid was washed with anhydrous ether (3x15 mL) and dried under vacuum to obtain 0.34 g of a light green solid with a yield of 90%.

[0041] The X-ray single crystal image of the product is as follows Figure 1 As shown, the molecular structure of 8-(diphenylphosphine)quinoline iron complex can be directly determined as:

[0042]

[0043] At the same time, if Figure 2 is the NMR phosphorus spectrum of the product, the specific data are: 31 P NMR (202MHz, CD2Cl2) δ10.06 (d, J = 14.6Hz), 3.82 (d, J = 14.6Hz); Figure 3 is the H NMR spectrum of the product, the specific data are: 1H NMR(500MHz,CD2Cl2)δ10.78(dt,J=5.5,1.8Hz,1H),8.50(dd,J=8.2,1.8Hz,1H),8.44–8.36(m,1H),8.1 2(ddd,J=12.2,6.8,3.0Hz,3H),7.85(d,J=8.0Hz,1H),7.81–7.72(m,4H),7.62(t,J=7.5Hz,1H),7.59–7. 46(m,4H),7.42–7.32(m,4H),7.32–7.26(m,1H),7.05(dtd,J=17.4,7.5,1.8Hz,3H),6.90(td,J=7.8,2. 2Hz,2H),6.86–6.79(m,1H),6.55(td,J=7.8,2.2Hz,2H),6.42(dd,J=8.2,5.5Hz,1H),6.16–6.07(m,2H); Figure 4 is the NMR carbon spectrum of the product, the specific data are: 13 C NMR (100MHz, CD2Cl2) δ164.1 (dd, J = 98.7, 49.1Hz), 157.0, 139.5, 138.1, 136.1, 133.4, 130.2, 129.9, 128.2, 126.6–125.0 (m), 122.5, 121.9. Figures 2 to 4 The accuracy of the structure was verified by hydrogen, carbon, and phosphorus. Figures 1 to 4 The product can be confirmed to be 8-(diphenylphosphine)quinoline iron complex.

[0044] Example 2

[0045] Screening of aprotic polar solvents:

[0046] The experimental conditions and feed amount of this embodiment are the same as those of embodiment 1, and different aprotic polar solvents are selected for the experiment, as shown below:

[0047] Serial number Aprotic polar solvents Yield 1 Tetrahydrofuran 90.0% 2 Dimethyl sulfoxide 88.5% 3 N,N-Dimethylformamide 82.3% 4 1,3-Dimethyl-2-imidazolidinone 82.0% 5 Hexamethylphosphoric acid triamide 85.5%

[0048] By comparing the above table, it can be concluded that when 1,3-dimethyl-2-imidazolidinone is selected as the solvent, the reaction yield is the lowest, which is only 82.0%. When dimethyl sulfoxide, N,N-dimethylformamide, and hexamethylphosphoric triamide are selected as the solvent, the reaction yields are 88.5%, 82.3% and 85.5%, respectively. When tetrahydrofuran is selected as the solvent, the reaction yield is the highest, which is 90.0%. In summary, the present invention selects tetrahydrofuran as the reaction solvent.

[0049] Example 3

[0050] Reaction temperature screening:

[0051] The experimental conditions and feed amount of this embodiment are the same as those of embodiment 1, and different reaction temperatures are selected for the experiment, as shown below:

[0052] Serial number Temperature(℃) Yield 1 40 20.3% 2 60 90.0% 3 80 90.1%

[0053] From the comparison in the above table, it can be concluded that the reaction yield is positively correlated with the reaction temperature. When the reaction temperature is lower than 40°C, the temperature in this range is not suitable for the catalytic system. When the reaction temperature is 60°C, the maximum reaction yield is 90.0%. However, when the temperature is further increased, the reaction yield does not increase significantly. In summary, the present invention selects 60°C as the reaction temperature.

[0054] Example 4

[0055] Application of 8-(diphenylphosphine)quinoline iron complex catalyst in the hydrogenation of (2S)-N-Boc-4-dimethylaminomethylene pyroglutamate methyl ester to (2S,4S)-N-Boc-4-methyl pyroglutamate methyl ester:

[0056] In a 50mL stainless steel autoclave, 15mg 8-(diphenylphosphine)quinoline iron complex catalyst FeCl2(DPPQ)2, 25mL ethanol, and 2.98g (0.01mol) of (2S)-N-Boc-4-dimethylaminomethylene pyroglutamic acid methyl ester were added in sequence, and magnetic stirring was performed for 10 minutes to obtain a mixed reaction slurry. The autoclave was sealed, and hydrogen was replaced three times in the autoclave, and the H2 pressure was filled to 1MPa. The temperature was maintained at 25°C, and the stirring reaction time was 5 hours. After the reaction was completed, the solid was filtered, and the 8-(diphenylphosphine)quinoline iron complex catalyst FeCl2(DPPQ)2 was recycled 10 times; the filtrate was decompressed to dry the solvent, and the residue was 2.63g of crude (2S, 4S)-N-Boc-4-methylpyroglutamic acid methyl ester, with a gas chromatography content of 92% and a yield of 94%; the NMR data of the product are as follows:

[0057] like Figure 5 As shown, the NMR hydrogen spectrum of the product is: 1 H NMR (400MHz, CDCl3): δ4.50 (dd, J = 8.3, 7.2Hz, 1H), 3.78 (s, 3H), 2.66–2.51 (m, 2H), 1.70–1.58 (m, 1H), 1.49 (s, 9H), 1.26 (d, J = 6.9Hz, 3H).

[0058] like Figure 6 As shown, the NMR carbon spectrum of the product is: 13C NMR (100MHz, CDCl3): δ175.67,172.01,149.31,83.53,57.29,52.41,37.41,29.63,27.78,16.02.

[0059] like Figure 7 As shown, the nuclear magnetic DEPT spectrum of the product is: DEPT-135 (100 MHz, CDCl3): δ57.29, 52.41, 37.41, 29.63, 27.78, 16.02.

[0060] pass Figure 5-7 The NMR spectrum of (2S, 4S)-N-Boc-4-methylpyroglutamate prepared in this example is consistent with the standard sample. It also shows that the 8-(diphenylphosphine)quinoline iron complex catalyst can play a good catalytic role in the preparation of (2S, 4S)-N-Boc-4-methylpyroglutamate.

[0061] Example 5

[0062] Application of 8-(diphenylphosphine)quinoline iron complex catalyst in the preparation of crude minocycline hydrochloride by selective hydrogenation of minocycline intermediate hydrogenated azo compound:

[0063] Add 60 ml of methanol, 5 g of concentrated hydrochloric acid and 14.26 g of hydrogenated azo compound (0.02 mol) to a 100 ml hydrogenation kettle, stir to dissolve, and then add 15 mg of catalyst FeCl2(DPPQ)2. After nitrogen replacement, replace the reactor with hydrogen three times, fill it with hydrogen at 1.0 MPa, and keep the pressure at 30°C for 6 hours. After that, release the hydrogen, replace the nitrogen, add 10 g of 37% formaldehyde solution, replace the nitrogen once again, replace the reactor with hydrogen three times, fill it with hydrogen at 1.0 MPa, and keep the pressure at 30°C for 6 hours. After the reaction is completed, replace the nitrogen, filter, and the solid is the catalyst FeCl2(DPPQ)2, which is washed with methanol. The filtrate is transferred to a 250 ml flask, cooled to 0°C, adjusted to pH 3.0 with ammonia water, filtered, and the solid is crude minocycline hydrochloride, which is 7.5 g after drying, with a yield of 75.8%. Figure 8 As shown, the H NMR spectrum of the product of this example is consistent with that of the standard sample.

[0064] It can be concluded from the application of Example 4 and Example 5 that the 8-(diphenylphosphine)quinoline iron complex catalyst has good selective catalytic hydrogenation performance and has good promotion and application value. In addition, the catalyst exhibits good catalytic performance, mild reaction conditions, high reaction yield and the like in the examples.

[0065] It is understood that the above specific description of the present invention is only used to illustrate the present invention and is not limited to the technical solutions described in the embodiments of the present invention. Those skilled in the art should understand that the present invention can still be modified or replaced by equivalents to achieve the same technical effects; as long as the use requirements are met, they are within the protection scope of the present invention.

Claims

1. An application of 8-(diphenylphosphine)quinoline iron complex catalyst, characterized in that: The 8-(diphenylphosphine)quinoline iron complex catalyst is used for the preparation of (2S, 4S)-N-Boc-4-methylpyroglutamate methyl ester and minocycline hydrochloride crude product, and the 8-(diphenylphosphine)quinoline iron complex catalyst has a structure of the following formula I: The catalyst uses 8-(diphenylphosphine)quinoline as a framework to coordinate iron ions to form an 8-(diphenylphosphine)quinoline iron complex catalyst, and the complex catalyst is a multi-dentate ligand.

2. The use of the 8-(diphenylphosphine)quinoline iron complex catalyst according to claim 1, characterized in that: The preparation method of (2S, 4S)-N-Boc-4-methylpyroglutamate methyl ester is as follows: N -Boc-4-dimethylaminomethylene pyroglutamic acid methyl ester is used as raw material and 8-(diphenylphosphine)quinoline iron complex is used as catalyst to obtain the product by selective hydrogenation reaction. The reaction formula is as follows: 。 3. The use of the 8-(diphenylphosphine)quinoline iron complex catalyst according to claim 1, characterized in that: The preparation method of (2S, 4S)-N-Boc-4-methylpyroglutamate methyl ester uses a minocycline intermediate hydrogenated azo compound as a raw material and 8-(diphenylphosphine)quinoline iron complex as a catalyst for selective hydrogenation reaction to obtain the product, and the reaction formula is as follows: 。